The Tisch Cancer Institute

Cancer Mechanisms

The main goal of the Cancer Mechanisms (CM) Program of The Tisch Cancer Institute (TCI) is to facilitate basic research that is pertinent to improving the diagnosis, treatment, and prevention of cancer. The premise of our program is that basic research on genetic, biochemical, and developmental pathways that drive cancer initiation and progression will reveal novel therapeutic targets for cancer. We recognize that effective identification and characterization of therapeutic targets must be grounded in detailed studies of human disease. CM investigators study important aspects of cancer development, perform gene discovery research in model organisms ranging from fission yeast to human cells and tissues, and explore mechanisms of cancer cell sensitivity and resistance to targeted therapy. Others design and implement clinical trials for cancer therapeutics developed at the Icahn School of Medicine at Mount Sinai. All of these approaches contribute to our overall goal of translating basic research advances to the clinical setting. The membership is organized around three scientific themes focused on signaling networks, epithelial cancer, and chromatin regulation and repair to accomplish our overarching specific aims:

  • Elucidating critical pathways that drive cancer development
  • Identifying candidate therapeutics that effectively target these pathways
  • Fostering intra- and inter-program collaborations that accelerate novel target and therapy development
  • Training an outstanding cadre of graduate students, and postdoctoral and clinical fellows in cancer biology